

**Figure 1. Disease Areas of Pfizer's Portfolio: Heat Map of Racial and Ethnic Disparities in Incidence, Prevalence and Disease Severity\***

Disease	Incidence/ Prevalence	AA Disparity Incidence/ Prevalence	AA Disparity in Severity	Hispanic Disparity Incidence/ Prevalence	Hispanic Disparity in Severity	Citations
<b>Oncology</b>						
Prostate Cancer	3	2	2	0	1	31, 32†, 33, 34, 35
Lung Cancer	3	2	2	0	0	36, 37, 35
Breast Cancer	3	0	2	0	1	35, 38†, 39, 40, 41, 42, 43†
Bladder Cancer	2	0	2	1	2	44, 45
Colorectal Cancer	2	2	2	0	1	35, 46, 47, 48†
Head and Neck Cancer	2	2	2	ND	2	49†, 50†, 51†, 52, 53
Melanoma	2	0	3	0	1	54, 55
Multiple Myeloma	1	3	1	2	1	12, 11, 56†
<b>Inflammation and Immunology</b>						
Ankylosing Spondylitis	1	0	3	1	2	57†, 58, 59†, 60
Rheumatoid Arthritis	1	1	1	0	2	61, 62, 63†, 64†, 65†
Osteoarthritis	3	1	2	1	2	66†, 67†, 68†, 69, 70†, 71†, 72†, 73†, 74
Inflammatory Bowel Disease	1	0	1	0	0	75†, 76, 77†, 78†, 79†, 80†, 81†, 82, 83†
Atopic Dermatitis	3	2	2	2	2	84†, 85†, 86†, 87, 88, 89
Psoriasis	2	0	2	0	ND	90, 91, 92
Hidradenitis Suppurativa	1	3	2	ND	2	93†, 94†, 95†, 96†, 13†
Vitiligo	1	1	2	2	1	97†, 98†, 99†, 100†
Alopecia Areata	2	3	2	1	2	101†, 102†
Stasis dermatitis	2	0	2	0	ND	103, 104††
Systemic Lupus Erythematosus	1	3	2	2	2	17†, 19†, 14†, 16†, 15†, 20, 18†
<b>Internal Medicine</b>						
Diabetes Mellitus	2	2	3	2	2	26, 29†, 28, 27†, 30†
Hypertriglyceridemia	3	0	1	2	ND	105†, 106†, 107†, 108†, 109, 110†
Obesity	3	2	ND	3	ND	23, 24, 22†, 25
Pain	3	0	3	0	2	111†, 112†, 113†, 114
Nonalcoholic Steatohepatitis	2	0	1	2	1	115†, 21, 116, 117, 118, 119†
Pulmonary Arterial Hypertension	0	1	1	1	1	120†, 121†, 122†

Rare Disease							
LMNA-Related Dilated Cardiomyopathy	0	3	ND	ND	ND	123†	
Growth Hormone Deficiency	0	1	2	1	ND	124†, 125†	
Hemophilia	0	0	ND	1	2	126, 127	
Duchenne Muscular Dystrophy	0	0	ND	ND	1	128, 129†, 130	
Focal Segmental Glomerulosclerosis	1	3	1	ND	ND	131‡, 132†, 133†	
Achondroplasia	0	ND	ND	0	ND	134, 135†‡	
Idiopathic Thrombocytopenic Purpura	0	0	2	ND	ND	136‡, 137†, 138	
Sickle Cell Anemia	0	3	ND	0	ND	139, 140†	
Vaccines							
Lyme Disease	1	0	ND	0	ND	141, 142†‡, 143	
Clostridium Difficile Colitis	2	0	2	1	0	144, 145	
Streptococcus Pneumoniae	2	2	1	2	ND	146†, 147†, 148†, 149†, 150†, 151†	
Group B Streptococcus	2	2	2	2	ND	152†, 153, 154†‡	
Meningococcal Meningitis	0	2	2	ND	ND	155, 149‡, 156†	
Abbreviations: ND=no data; NHW=non-Hispanic White; PY=person-year							
Scoring Legend:							
Incidence (cancers and vaccines): 0=<1 per 100,000 PYs; 1=1 to 20; 2=20 to 50 per 100,000 PYs; 3=>50 per 100,000 PYs							
Prevalence (all other diseases): 0=<0.1%; 1=0.1 to 1%; 2=1 to 10%; 3=>10%							
Incidence/prevalence disparity: 0=Lower than NHW; 1=Equal to NHW; 2=Modest excess compared to NHW; 3=Significant excess compared to NHW							
Survival disparity: 0=Greater than NHW; 1=Equal to NHW; 2=Modestly worse than NHW;3=Significantly worse than NHW							
Severity disparity: 0=Lower than NHW; 1=Equal to NHW; 2=Suggestion in the literature more severely impacted than NHW; 3=Quantitative evidence of greater severity than NHW							
*For cancers, severity was assessed based on survival. For non-cancers, severity based on rates of complications, hospitalization, response to therapy, etc.							
† Source does not meet criteria for generalizability							
‡ Source published prior to 2010							